GSK481 is primarily utilized in research settings to study the role of RIP1 kinase in various inflammatory and degenerative diseases. It serves as a potent and selective inhibitor of RIP1 kinase, enabling scientists to investigate the pathways and mechanisms involved in cell death processes such as necroptosis. By inhibiting RIP1 kinase, GSK481 helps researchers understand its contribution to conditions like Alzheimer's disease, multiple sclerosis, and inflammatory bowel disease. This compound is also used in preclinical studies to explore potential therapeutic strategies targeting RIP1 kinase for the treatment of these diseases. Its application is crucial in advancing the development of novel drugs aimed at modulating cell death pathways to improve patient outcomes.